These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 20215447

  • 1. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.
    Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.
    Diabetes Care; 2010 Jun; 33(6):1224-9. PubMed ID: 20215447
    [Abstract] [Full Text] [Related]

  • 2. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Nutter B, Jain A, Atreja A, Zimmerman RS.
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [Abstract] [Full Text] [Related]

  • 3. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
    Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.
    Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
    [Abstract] [Full Text] [Related]

  • 4. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.
    Andersson C, Gislason GH, Jørgensen CH, Hansen PR, Vaag A, Sørensen R, Mérie C, Olesen JB, Weeke P, Schmiegelow M, Norgaard ML, Køber L, Torp-Pedersen C.
    Diabetes Res Clin Pract; 2011 Oct; 94(1):119-25. PubMed ID: 21831467
    [Abstract] [Full Text] [Related]

  • 5. Hypoglycemia in hospitalized patients treated with sulfonylureas.
    Deusenberry CM, Coley KC, Korytkowski MT, Donihi AC.
    Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
    Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA.
    CMAJ; 2006 Jan 17; 174(2):169-74. PubMed ID: 16415461
    [Abstract] [Full Text] [Related]

  • 13. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
    Khalangot M, Tronko M, Kravchenko V, Kovtun V.
    Diabetes Res Clin Pract; 2009 Dec 17; 86(3):247-53. PubMed ID: 19796836
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
    Bell DS.
    Clin Ther; 2004 Nov 17; 26(11):1714-27. PubMed ID: 15639686
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.